Why Agility is Mission-Critical in Today’s Fast-Paced Life Sciences Industry
Adopting an agile mindset unlocks the flexibility required to respond to market changes— here’s how Catalant can help.
The life science industry is evolving rapidly, especially with respect to technology, compliance requirements, and talent needs. In a business landscape marked by uncertainty and constant change, the risk of being too rigid is high: missed opportunities, slower time-to-market, and diminished patient outcomes. What’s required is agility.
Agility means your strategy, operations, and talent management approaches are flexible and able to go where the industry trends are heading. It also means:
- Maintaining business continuity despite uncertainty
- Driving continuous improvement
- Optimizing investments to achieve results
The reality is, most life science and pharmaceutical organizations face obstacles when it comes to adopting an agile mindset – we learned at a recent industry conference that as few as 8% of organizations apply this mindset.
About half of life sciences executives in a recent survey even admitted that they had to forego business opportunities because they lacked access to the right talent at the right time, stalling growth and innovation.
Agility and AI
Let’s look at one fast-evolving trend impacting life sciences today: artificial intelligence.
In one example, researchers are now leveraging AI to predict protein structure, which was the subject of the 2024 Nobel Prize awarded for Chemistry.
The Nobel Prize announcement noted, “[c]hemists have long dreamed of fully understanding and mastering the chemical tools of life – proteins. This dream is now within reach. [The prize recipients] have successfully utilised artificial intelligence to predict the structure of almost all known proteins, learned how to master life’s building blocks, and create entirely new proteins. The potential of their discoveries is enormous.”
AI is just one of many emerging industry trends that can help revolutionize drug discovery by:
- accelerating the pace of discovery,
- taking massive volumes of research and synthesizing the data to identify potential drug candidates faster than ever, and
- reducing operational costs.
More life sciences organizations will be embedding AI into their research and development pipelines, revolutionizing drug discovery. But fully realizing those gains will require integrating AI across an organization, and that requires the adoption of business agility.
Agility in Practice
Let’s explore an example of agility mindset in action. Michael Peteoustas, Astellas Head of US Commercial, spoke at the recent Pharma USA 2025 conference about how agility is transforming operations at Astellas.
Peteoustas highlighted 5 specific areas where improved agility had helped the pharmaceutical company improve competitiveness:
1. Faster commercialization, meaning investments in research can turn into treatments, patient care, and revenues in shorter cycles.
2. Continuous customer feedback, giving Astrellas timely, more actionable understanding of what solutions patients currently need.
3. Improved cross-functional collaboration, meaning that traditional silos get broken down and more relevant data gets shared across the entire organization in order to achieve common goals.
4. Faster decision-making when the right people have the right information to make timely decisions that drive mission-critical impacts.
5. Closer connection to patients, enabling Astella to target resources where they’ll make the most impact.
Peteoustas summed up his views afterwards, saying:
“Agile methodologies are reshaping our industry’s approach to product development and commercialization, making us faster, more efficient, and able to bring greater value to our patients and customers. They’re fundamentally changing how Astellas does business.”
Partnering on Agility
Adopting an agile mindset requires organizational shifts. It helps to have a strategic partner like Catalant. Solving problems you haven’t faced before, adopting major transformation, and building new capabilities requires the expertise of people who’ve solved similar problems before in similar organizations.
Catalant enables you to find and deploy exactly the right expertise you need when you need it, for as long as you need it.
In turn, operations, commercial, and marketing teams gain the bandwidth to focus on critical business priorities, balancing innovation with compliance.
Interested in bringing more agility to your life sciences organization?
Let’s TalkMeet the Author
Laura Polin has a proven track record of driving business growth in the life sciences, having spent 18 years at Pfizer in marketing leadership roles. She currently works as a full-time consultant, partnering with life science organizations to develop and implement strategies, as well as grow and develop cultures of continuous improvement.
Organizational agility serves as a primary driver for faster commercialization, enabling research investments to transition into patient treatments and revenue in shorter cycles. According to Catalant consultant Laura Polin, rigid structures often lead to slower time-to-market and diminished patient outcomes. By adopting agile methodologies, firms can break down traditional silos and foster cross-functional collaboration, allowing mission-critical information to reach decision-makers faster. This operational flexibility ensures that life sciences organizations can pivot resources toward the most impactful therapeutic areas as market trends shift.
A lack of access to specialized talent at critical moments forces nearly half of life sciences executives to forego significant business opportunities, stalling growth and innovation. While emerging technologies like artificial intelligence offer enormous potential, the inability to deploy specific expertise prevents organizations from embedding these tools into research and development pipelines. This talent gap acts as a bottleneck for drug discovery. Agility in talent management—specifically the ability to find and deploy on-demand expertise—is therefore essential for maintaining business continuity and optimizing investments in a volatile environment.
Artificial intelligence revolutionizes drug discovery by synthesizing massive research volumes to identify potential drug candidates faster and at a lower operational cost. Integrating AI across the enterprise requires business agility to ensure that data-driven insights are actionable across research, development, and commercial functions. Organizations that successfully embed these capabilities can achieve a level of predictive accuracy that was previously considered a long-term theoretical goal.
Integrating continuous feedback loops into an agile framework provides a timely and actionable understanding of evolving patient needs. This proximity to the customer enables pharmaceutical companies to target resources with higher precision. Rather than relying on static annual reports, agile organizations use real-time feedback to refine their value propositions and improve guest or patient experiences. This closer connection to the market ensures that commercial strategies remain relevant despite rapid changes in technology, compliance requirements, and patient expectations.
